JP2020533345A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533345A5
JP2020533345A5 JP2020514550A JP2020514550A JP2020533345A5 JP 2020533345 A5 JP2020533345 A5 JP 2020533345A5 JP 2020514550 A JP2020514550 A JP 2020514550A JP 2020514550 A JP2020514550 A JP 2020514550A JP 2020533345 A5 JP2020533345 A5 JP 2020533345A5
Authority
JP
Japan
Prior art keywords
methyl
phenyl
carboxamide
biphenyl
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020514550A
Other languages
English (en)
Japanese (ja)
Other versions
JP7394747B2 (ja
JP2020533345A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/074662 external-priority patent/WO2019053090A1/en
Publication of JP2020533345A publication Critical patent/JP2020533345A/ja
Publication of JP2020533345A5 publication Critical patent/JP2020533345A5/ja
Application granted granted Critical
Publication of JP7394747B2 publication Critical patent/JP7394747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020514550A 2017-09-13 2018-09-12 ジフェニル誘導体及びその使用 Active JP7394747B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558065P 2017-09-13 2017-09-13
US62/558,065 2017-09-13
PCT/EP2018/074662 WO2019053090A1 (en) 2017-09-13 2018-09-12 DIPHENYL DERIVATIVES AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2020533345A JP2020533345A (ja) 2020-11-19
JP2020533345A5 true JP2020533345A5 (enExample) 2021-10-21
JP7394747B2 JP7394747B2 (ja) 2023-12-08

Family

ID=63579358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514550A Active JP7394747B2 (ja) 2017-09-13 2018-09-12 ジフェニル誘導体及びその使用

Country Status (8)

Country Link
US (1) US10633350B2 (enExample)
EP (1) EP3681883B1 (enExample)
JP (1) JP7394747B2 (enExample)
CN (1) CN111094278B (enExample)
ES (1) ES2985747T3 (enExample)
TW (1) TW201920112A (enExample)
UY (1) UY37872A (enExample)
WO (1) WO2019053090A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111848552B (zh) * 2019-04-28 2023-12-19 南京富润凯德生物医药有限公司 一种3-(取代苯基)氧杂环丁烷-3-羧酸及其中间体的制备方法及应用
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
EP4330232A1 (en) * 2021-04-26 2024-03-06 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
GB202113186D0 (en) * 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
US20070191371A1 (en) 2006-02-14 2007-08-16 Kalypsys, Inc. Heterocyclic modulators of ppar
US20090318410A1 (en) 2006-10-30 2009-12-24 Novartis Ag Imidazopyridazines as lipid kinase inhibitors
TWI579274B (zh) 2012-04-20 2017-04-21 龍馬躍公司 製備1-芳基-5-烷基吡唑化合物的改良方法
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
JP2015524483A (ja) * 2012-08-09 2015-08-24 ニューロポア セラピーズ,インコーポレイティド Pi3−キナーゼシグナリング経路の調節因子としてのアリール及びヘテロアリールで置換されたベンゼン誘導体
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk

Similar Documents

Publication Publication Date Title
RU2347777C2 (ru) Двойные агонисты nk1/nk3 для лечения шизофрении
JP4638355B2 (ja) チアゾール誘導体
JP2009529047A5 (enExample)
CA2671614C (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP5829915B2 (ja) 複素環式置換基を有するアリール化合物およびそれらの使用
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
JP2018044008A5 (enExample)
EP3710002A2 (en) Degraders and degrons for targeted protein degradation
JP2012532931A5 (enExample)
US20140213575A1 (en) 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines
JP2017530999A5 (enExample)
JP2012501312A5 (enExample)
JP2013523884A5 (enExample)
RU2012117398A (ru) Бензоксазепиновые ингибиторы pi3 и способы применения
JP2022514650A5 (enExample)
AU2015308522A1 (en) Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
JP2018509442A (ja) Fgfr4阻害剤としてのホルミル化n−複素環式誘導体
RU2007130153A (ru) Амидные производные
KR20250081951A (ko) 금속 채널 활성화제를 포함하는 병용 요법
EP2558126A2 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
IL319619A (en) Phthalazine derivatives used as NOD-LIKE PROTEIN 3 receptor inhibitors
EP4618980A1 (en) Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases
JP2024506047A5 (enExample)
AU2012276651A1 (en) Antipruritic agent
JP2017516772A5 (enExample)